TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05763953: The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients)

Sponsor: Milestone Pharmaceuticals Inc. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 60 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$1,460,800

Rescue Site Savings

+$962,800

Unlock Full NCT05763953 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05763953 Rescue Dossier →